Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1955 1
1967 1
1971 1
1974 1
1975 2
1977 1
1978 2
1981 5
1982 4
1984 3
1985 2
1986 5
1987 7
1988 6
1989 7
1990 5
1991 4
1992 6
1993 2
1994 9
1995 5
1996 6
1997 8
1998 3
1999 9
2000 12
2001 7
2002 11
2003 12
2004 14
2005 11
2006 10
2007 14
2008 13
2009 23
2010 11
2011 13
2012 14
2013 11
2014 20
2015 18
2016 25
2017 20
2018 23
2019 22
2020 21
2021 26
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

419 results
Results by year
Filters applied: . Clear all
Page 1
Partitioning of cancer therapeutics in nuclear condensates.
Klein IA, Boija A, Afeyan LK, Hawken SW, Fan M, Dall'Agnese A, Oksuz O, Henninger JE, Shrinivas K, Sabari BR, Sagi I, Clark VE, Platt JM, Kar M, McCall PM, Zamudio AV, Manteiga JC, Coffey EL, Li CH, Hannett NM, Guo YE, Decker TM, Lee TI, Zhang T, Weng JK, Taatjes DJ, Chakraborty A, Sharp PA, Chang YT, Hyman AA, Gray NS, Young RA. Klein IA, et al. Among authors: decker tm. Science. 2020 Jun 19;368(6497):1386-1392. doi: 10.1126/science.aaz4427. Science. 2020. PMID: 32554597 Free PMC article.
Breast cancer prognostic classification in the molecular era: the role of histological grade.
Rakha EA, Reis-Filho JS, Baehner F, Dabbs DJ, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR, Palacios J, Richardson AL, Schnitt SJ, Schmitt FC, Tan PH, Tse GM, Badve S, Ellis IO. Rakha EA, et al. Among authors: decker t. Breast Cancer Res. 2010;12(4):207. doi: 10.1186/bcr2607. Epub 2010 Jul 30. Breast Cancer Res. 2010. PMID: 20804570 Free PMC article. Review.
Second International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions).
Rageth CJ, O'Flynn EAM, Pinker K, Kubik-Huch RA, Mundinger A, Decker T, Tausch C, Dammann F, Baltzer PA, Fallenberg EM, Foschini MP, Dellas S, Knauer M, Malhaire C, Sonnenschein M, Boos A, Morris E, Varga Z. Rageth CJ, et al. Among authors: decker t. Breast Cancer Res Treat. 2019 Apr;174(2):279-296. doi: 10.1007/s10549-018-05071-1. Epub 2018 Nov 30. Breast Cancer Res Treat. 2019. PMID: 30506111 Free PMC article. Review.
Pol II phosphorylation regulates a switch between transcriptional and splicing condensates.
Guo YE, Manteiga JC, Henninger JE, Sabari BR, Dall'Agnese A, Hannett NM, Spille JH, Afeyan LK, Zamudio AV, Shrinivas K, Abraham BJ, Boija A, Decker TM, Rimel JK, Fant CB, Lee TI, Cisse II, Sharp PA, Taatjes DJ, Young RA. Guo YE, et al. Among authors: decker tm. Nature. 2019 Aug;572(7770):543-548. doi: 10.1038/s41586-019-1464-0. Epub 2019 Aug 7. Nature. 2019. PMID: 31391587 Free PMC article.
Mediator Condensates Localize Signaling Factors to Key Cell Identity Genes.
Zamudio AV, Dall'Agnese A, Henninger JE, Manteiga JC, Afeyan LK, Hannett NM, Coffey EL, Li CH, Oksuz O, Sabari BR, Boija A, Klein IA, Hawken SW, Spille JH, Decker TM, Cisse II, Abraham BJ, Lee TI, Taatjes DJ, Schuijers J, Young RA. Zamudio AV, et al. Among authors: decker tm. Mol Cell. 2019 Dec 5;76(5):753-766.e6. doi: 10.1016/j.molcel.2019.08.016. Epub 2019 Sep 25. Mol Cell. 2019. PMID: 31563432 Free PMC article.
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Müller S, Link H, Niederle N, Rost A, Höffkes HG, Moehler M, Lindig RU, Modest DP, Rossius L, Kirchner T, Jung A, Stintzing S. Heinemann V, et al. Among authors: decker t. Lancet Oncol. 2014 Sep;15(10):1065-75. doi: 10.1016/S1470-2045(14)70330-4. Epub 2014 Jul 31. Lancet Oncol. 2014. PMID: 25088940 Clinical Trial.
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial.
Heinemann V, von Weikersthal LF, Decker T, Kiani A, Kaiser F, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Moehler M, Scheithauer W, Held S, Miller-Phillips L, Modest DP, Jung A, Kirchner T, Stintzing S. Heinemann V, et al. Among authors: decker t. Br J Cancer. 2021 Feb;124(3):587-594. doi: 10.1038/s41416-020-01140-9. Epub 2020 Nov 6. Br J Cancer. 2021. PMID: 33154570 Free PMC article. Clinical Trial.
Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.
Stintzing S, Wirapati P, Lenz HJ, Neureiter D, Fischer von Weikersthal L, Decker T, Kiani A, Kaiser F, Al-Batran S, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Moehler M, Scheithauer W, Held S, Modest DP, Jung A, Kirchner T, Aderka D, Tejpar S, Heinemann V. Stintzing S, et al. Among authors: decker t. Ann Oncol. 2019 Nov 1;30(11):1796-1803. doi: 10.1093/annonc/mdz387. Ann Oncol. 2019. PMID: 31868905 Free PMC article. Clinical Trial.
Breast carcinomas of low malignant potential.
Schnitt SJ, Fend F, Decker T. Schnitt SJ, et al. Among authors: decker t. Virchows Arch. 2021 Jul 22. doi: 10.1007/s00428-021-03163-w. Online ahead of print. Virchows Arch. 2021. PMID: 34292391 Review.
419 results